Alterity Therapeutics (AU:ATH)

ASX:ATH

ATH

Alterity Therapeutics

RESEARCH TOOLSreports

Want to see AU:ATH full AI Analyst Report?

Alterity Therapeutics (ATH) Price & Analysis

37 Followers

ATH Stock Chart & Stats

AU$0.01

>-AU$0.01(-10.00%)

At close: Jan 09 4:00 PM EST

AU$0.01

>-AU$0.01(-10.00%)

Day’s Range― - ―

52-Week RangeAU$0.35 - AU$0.85

Previous CloseN/A

Volume25.42M

Average Volume (3M)16.33M

Market Cap

AU$130.51M

Enterprise ValueAU$78.21M

Total Cash (Recent Filing)AU$49.20M

Total Debt (Recent Filing)AU$163.91K

Price to Earnings (P/E)―

Beta2.09

Next Earnings

Mar 04, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.01

Shares Outstanding217,508,870

10 Day Avg. Volume24,202,939

30 Day Avg. Volume16,327,471

Financial Highlights & Ratios

PEG Ratio0.08

Price to Book (P/B)1.51

Price to Sales (P/S)11.76

P/FCF Ratio-5.59

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$0.95

Price Target Upside9400.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.07

Revenue Forecast (FY)AU$4.80M

Bulls Say, Bears Say

Bulls Say

Proprietary Lead ProgramsOwnership of small‑molecule, iron‑modulating compounds and focus on MSA represent a clear scientific differentiation and intellectual property basis. A disease‑modifying approach in a high unmet‑need neurodegenerative area supports durable strategic value and potential for licensing or acquisition.

Very Low LeverageExtremely low debt reduces financial distress risk and preserves balance sheet flexibility. For a clinical‑stage biotech, minimal leverage lowers bankruptcy risk during lengthy trials and makes the company more attractive for partnerships or milestone financing without high fixed interest obligations.

Strong Revenue GrowthA 46.03% top-line increase indicates meaningful commercial or grant progress and supports continued R&D investment. Sustained revenue expansion over quarters can improve trial funding options, increase partner interest, and reduce sole reliance on dilutive financing over the medium term.

Bears Say

No Recurring Product RevenueAbsence of commercialized products means operations depend on periodic equity or financing rounds. That reliance raises dilution and financing execution risk, and without recurring revenues or sizable partnership inflows the company faces structural funding pressure throughout multi‑year clinical development.

Weak Cash GenerationNegative operating and free cash flow with sharply declining FCF growth indicate poor conversion of activities into liquidity. This reduces runway, increases reliance on external funding, and can force hurried financing or unfavorable partner terms, impeding long‑term program execution.

Persistent Negative MarginsConsistent negative EBIT and net margins show the company is not generating operational profits. For a clinical‑stage biotech with long development timelines, sustained losses erode equity and raise dilution risk, constraining the firm's ability to self‑fund later‑stage trials.

Alterity Therapeutics News

Alterity Therapeutics assumed with a Buy at Ladenburg

Ladenburg analyst Caroline Palomeque assumed coverage of Alterity Therapeutics (ATHE) with a Buy rating and $10 price target...

5d ago

ATHE

Alterity Therapeutics achieves alignment with FDA on program for ATH434 in MSA

Alterity Therapeutics (ATHE) announced the outcome of its End-of-Phase 2 meeting with the FDA, achieving alignment on the...

12d ago

ATHE

Alterity Therapeutics management to meet with BTIG

Meeting to be held in San Francisco on June 10-11 hosted by BTIG. Published first on TheFly –...

18d ago

ATHE

Alterity Consolidates Shares and Temporarily Changes ASX Ticker Ahead of Phase 3 Push

Alterity Therapeutics ( ($AU:ATH) ) just unveiled an update. Alterity Therapeutics has commenced a 1-for-50 consolidation of its...

17d ago

Alterity Therapeutics Updates Registered Office Address in Melbourne

Alterity Therapeutics ( ($AU:ATH) ) just unveiled an update. Alterity Therapeutics has changed its registered office address to...

18d ago

Alterity Investors Approve Resolutions, Clearing Path Toward Pivotal MSA Trial

Alterity Therapeutics ( ($AU:ATH) ) has shared an update. Alterity Therapeutics said shareholders passed resolutions at its 2026...

23d ago

Alterity Therapeutics publishes quantitative susceptibility mapping MRI data

Alterity Therapeutics (ATHE) announced the publication of a peer-reviewed study in NeuroImage, demonstrating that quantitative susceptibility mapping MRI...

1M ago

ATHE

Alterity Therapeutics Showcases MSA Program Ahead of Phase 3 Push

Alterity Therapeutics ( ($AU:ATH) ) has shared an announcement. Alterity Therapeutics will showcase multiple aspects of its Multiple...

2M ago

Alterity advances ATH434 toward Phase 3 in Multiple System Atrophy after FDA backing

Alterity Therapeutics ( ($AU:ATH) ) has issued an update. Alterity Therapeutics reported steady progress in advancing its lead...

2M ago

Alterity Therapeutics Sets Virtual General Meeting for May 29, 2026

Alterity Therapeutics ( ($AU:ATH) ) has provided an announcement. Alterity Therapeutics has called a virtual General Meeting of...

2M ago

Alterity Therapeutics receives FDA feedback after second ATH434 Type C meeting

Alterity Therapeutics (ATHE) announced it has received regulatory feedback following a Type C meeting with the FDA regarding...

2M ago

ATHE

Alterity Wins FDA Backing on CMC Plan for ATH434 Phase 3 in Multiple System Atrophy

Alterity Therapeutics ( ($AU:ATH) ) just unveiled an update. Alterity Therapeutics has secured positive feedback from the U.S....

2M ago

Alterity Therapeutics presents new data analyses from ATH434 trial

Alterity Therapeutics (ATHE) announced the presentation of new data analyses from the Phase 2 trial of ATH434, demonstrating...

2M ago

ATHE

Alterity’s ATH434 Shows Phase 2 Efficacy Signal in MSA on New Composite Scale

An announcement from Alterity Therapeutics ( ($AU:ATH) ) is now available. Alterity Therapeutics has unveiled new analyses from...

2M ago

ATH FAQ

What was Alterity Therapeutics’s price range in the past 12 months?

Alterity Therapeutics lowest share price was AU$0.35 and its highest was AU$0.85 in the past 12 months.

What is Alterity Therapeutics’s market cap?

Alterity Therapeutics’s market cap is AU$130.51M.

When is Alterity Therapeutics’s upcoming earnings report date?

Alterity Therapeutics’s upcoming earnings report date is Mar 04, 2027 which is in 256 days.

How were Alterity Therapeutics’s earnings last quarter?

Alterity Therapeutics released its earnings results on Feb 25, 2026. The company reported -AU$0.045 earnings per share for the quarter, missing the consensus estimate of -AU$0.029 by -AU$0.016.

Is Alterity Therapeutics overvalued?

According to Wall Street analysts Alterity Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Alterity Therapeutics pay dividends?

Alterity Therapeutics does not currently pay dividends.

What is Alterity Therapeutics’s EPS estimate?

Alterity Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Alterity Therapeutics have?

Alterity Therapeutics has 217,508,870 shares outstanding.

What happened to Alterity Therapeutics’s price movement after its last earnings report?

Alterity Therapeutics reported an EPS of -AU$0.045 in its last earnings report, missing expectations of -AU$0.029. Following the earnings report the stock price went down -9.091%.

Which hedge fund is a major shareholder of Alterity Therapeutics?

Currently, no hedge funds are holding shares in AU:ATH

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Alterity Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-30.19%

Trailing 12-Months

Asset Growth

481.25%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Alterity Therapeutics

Based in Melbourne, Australia, Alterity Therapeutics Limited, founded in 1997, is dedicated to the discovery and advancement of treatments for neurological conditions such as Alzheimer's, Huntington's, and Parkinson's diseases, among others. The company's primary drug candidate, ATH434, has successfully navigated Phase I clinical trials for Parkinson's disease. Additionally, it is progressing PBT2, an investigational compound for Alzheimer's disease that has completed Phase 2a clinical trials. The firm, previously known as Prana Biotechnology Limited, adopted its current name, Alterity Therapeutics Limited, in April 2019.

Alterity Therapeutics (ATH) Earnings & Revenues

Historic Earnings Reports

ATH Stock 12 Month Forecast

Average Price Target

AU$0.95

▲(9400.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"AU$0","1":"AU$1","-1":"-AU$1","-0.5":"-AU$0.5","0.5":"AU$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$0.95</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$0.95</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$0.95</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.395,0.4376923076923077,0.4803846153846154,0.5230769230769231,0.5657692307692308,0.6084615384615385,0.6511538461538462,0.6938461538461538,0.7365384615384616,0.7792307692307692,0.821923076923077,0.8646153846153846,0.9073076923076923,{"y":0.95,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.395,0.4376923076923077,0.4803846153846154,0.5230769230769231,0.5657692307692308,0.6084615384615385,0.6511538461538462,0.6938461538461538,0.7365384615384616,0.7792307692307692,0.821923076923077,0.8646153846153846,0.9073076923076923,{"y":0.95,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.395,0.4376923076923077,0.4803846153846154,0.5230769230769231,0.5657692307692308,0.6084615384615385,0.6511538461538462,0.6938461538461538,0.7365384615384616,0.7792307692307692,0.821923076923077,0.8646153846153846,0.9073076923076923,{"y":0.95,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.55,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.5,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.5,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.5,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.5,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.5,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.5,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.525,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.395,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >